Coherus BioSciences (CHRS) Tops Q3 EPS by 15c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.34 +16.52%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
PODC, CLIR, ARDS, More
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
PODC, CLIR, ARDS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.01), $0.15 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $70.77 million versus the consensus estimate of $58.98 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- JPMorgan Upgrades Taiwan Mobile Co Ltd (3045:TT) to Overweight
- MongoDB (MDB) PT Raised to $519 at Citizens on Improved Q2 Sales, Positive Diligence Data
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
